Parkinson's disease
Neurology· 6 reviewed drugs· 3432 cited findings behind them
What the regulatory reviews cover
This library contains regulatory review documents for several drugs indicated for Parkinson's disease. Onerji is indicated for motor fluctuations in advanced Parkinson's disease not sufficiently controlled by oral anti-Parkinson medicinal products, showing a reduction in OFF time of 2.1 vs 1.4 (ND0612 vs placebo). Exelon Patch is indicated for mild to moderate dementia associated with Parkinson’s disease (PDD), with an ADAS-cog mean change from baseline (15 cm patch) of -0.2. Xadago is for adult patients with idiopathic Parkinson’s disease as add-on therapy to levodopa, demonstrating a difference vs placebo in daily ON time without troublesome dyskinesia of 0.96 (safinamide 100 mg/day). Inbrija is for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease, showing an LS mean difference in UPDRS-III score (CVT-301 84mg vs placebo) of -3.92. Ongentys showed a difference in change from baseline in absolute OFF-time vs placebo (OPC 50 mg, FAS) of -54.31.
It is important to note that these drugs were studied in different trials, and therefore the figures presented are not directly comparable in a head-to-head manner. Ingrezza, while present in the library, is indicated for tardive dyskinesia, with an incidence of parkinson-like adverse events (INGREZZA) of 3 %.
The drugs — one cited result each
| Onerji Mitsubishi Tanabe Pharma | Reduction in OFF time (ND0612 vs placebo): 2.1 vs 1.4 Tanabe — Onerji EMA EPAR public assessment report (EMEA/H/C/, p.21 |
| Exelon Patch Novartis AG | ADAS-cog mean change from baseline (15 cm patch): -0.2 SANDOZ — Exelon FDA Review (NDA/BLA 022083, 2016), p.36 |
| Xadago Zambon | Difference vs placebo in daily ON time without troublesome dyskinesia (safinamide 100 mg/day): 0.96 Zambon — Xadago EMA EPAR public assessment report (EMEA/H/C/, p.60 |
| Ongentys Bial | Difference in change from baseline in absolute OFF-time vs placebo (OPC 50 mg, FAS): -54.31 Bial Portela C S A — Ongentys EMA EPAR public assessment rep, p.85 |
| Inbrija Merz Pharma | LS mean difference in UPDRS-III score (CVT-301 84mg vs placebo): -3.92 Merz — Inbrija EMA EPAR public assessment report (EMEA/H/C/0, p.47 |
| Ingrezza NEUROCRINE | Incidence of parkinson-like adverse events (INGREZZA): 3 % NEUROCRINE — Ingrezza FDA Review (NDA/BLA 209241, 2022), p.11 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Neurology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.